RT Journal Article
SR Electronic
T1 Mutations in genes <em>lpxL1, bamA</em> and <em>pmrB</em> impair the susceptibility of cystic fibrosis strains of <em>Pseudomonas aeruginosa</em> to murepavadin
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2023.10.09.561565
DO 10.1101/2023.10.09.561565
A1 Ghassani, Aya
A1 Triponney, Pauline
A1 Bour, Maxime
A1 Plesiat, Patrick
A1 Jeannot, Katy
A1 MucoMicrobes study Group
YR 2023
UL http://biorxiv.org/content/early/2023/10/13/2023.10.09.561565.abstract
AB Murepavadin is a peptidomimetic exhibiting specific inhibitory activity against Pseudomonas species. In the present study, its in vitro activity was assessed on 230 cystic fibrosis (CF) strains of P. aeruginosa isolated from twelve French hospitals, in comparison with twelve other antipseudomonal antibiotics. Although murepavadin is still in pre-clinical stage of development, 9.1% (n=21) of the strains displayed a resistance superior to 4 mg/L, a level at least 128-fold higher than the modal MIC value of the whole collection (≤ 0.06 mg/L). Whole-genome sequencing of these 21 strains along with more susceptible isogenic counterparts coexisting in the same patients revealed diverse mutations in genes involved in the synthesis (lpxL1 and lpxL2) or transport of lipopolysaccharides (bamA, lptD, and msbA), or encoding histidine kinases of two-component systems (pmrB and cbrA). Allelic replacement experiments with wild-type reference strain PAO1 confirmed that alteration of genes lpxL1, bamA and/or pmrB can increase murepavadin resistance from 8- to 32-fold. Furthermore, we found that specific amino-acid substitutions in histidine kinase PmrB (G188D, Q105P, and D45E) reduce the susceptibility of P. aeruginosa to murepavadin, colistin and tobramycin, three antibiotics used or intended to be used (murepavadin) in aerosols to treat colonized CF patients. Whether colistin or tobramycin may select mutants resistant to murepavadin or the opposite needs to be addressed by clinical studies.